These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31919937)

  • 1. Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.
    Augustin M; Jullien D; Martin A; Peralta C
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1174-1185. PubMed ID: 31919937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
    Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
    Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.
    Asawanonda P; Pattamadilok B; Chularojanamontri L; Chuamanochan M; Choonhakarn C; Chakkavittumrong P; Sangob N; Rajatanavin N
    Dermatol Ther; 2022 Dec; 35(12):e15958. PubMed ID: 36279306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
    Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
    Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
    Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice.
    Zhou J; Yuan Y; Liu Y; Chu M; Liu H; Liu Q; Wang R; Shao S; Wang G; Yu C
    Exp Dermatol; 2024 Jan; 33(1):e14890. PubMed ID: 37474877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
    Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
    Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
    [No Abstract]   [Full Text] [Related]  

  • 9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Secukinumab for the Treatment of Psoriasis: A Meta-Analysis of Pivotal Phase III Trials.
    Zhou Y; Zhang K; Ma X; Xie Z
    Dermatology; 2024; 240(2):271-281. PubMed ID: 37926074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
    Dastoli S; Passante M; Loconsole F; Mortato E; Balato A; Piccolo V; Guarneri C; Macca L; Provenzano E; Valenti G; D'Amico D; Micali G; Musumeci ML; Palazzo G; Foti C; Romita P; Fabbrocini G; Megna M; Sammarra I; Bennardo L; Patruno C
    J Dermatolog Treat; 2023 Dec; 34(1):2200868. PubMed ID: 37026590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients aged six years and older.
    Krajewski PK; Szepietowski JC
    Expert Rev Clin Immunol; 2023; 19(7):711-716. PubMed ID: 37191153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
    Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study.
    Zhao Y; Cai L; Liu XY; Zhang H; Zhang JZ
    Chin Med J (Engl); 2021 May; 134(11):1324-1328. PubMed ID: 33950871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A; Papavassilis C; Bhosekar V; Reinhardt M
    Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China.
    Wang Y; Wang X; Yu Y; Yuan L; Yu X; Yang B
    Dermatol Ther; 2021 Sep; 34(5):e15081. PubMed ID: 34339549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
    Ryoo JY; Yang HJ; Ji E; Yoo BK
    Ann Pharmacother; 2016 May; 50(5):341-51. PubMed ID: 26783352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study.
    Thaçi D; Körber A; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Duetting E; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):310-318. PubMed ID: 31541554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.